Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Income from Continuing Operations (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Income from Continuing Operations for 3 consecutive years, with 17990000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 8.54% to 17990000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 71506000.0 through Dec 2025, down 35.75% year-over-year, with the annual reading at 72839000.0 for FY2025, 28.63% down from the prior year.
  • Income from Continuing Operations hit 17990000.0 in Q4 2025 for Compass Therapeutics, down from 15817000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 7837000.0 in Q1 2023 to a low of 21066000.0 in Q2 2025.
  • Historically, Income from Continuing Operations has averaged 13889666.67 across 3 years, with a median of 13245500.0 in 2023.
  • Biggest YoY gain for Income from Continuing Operations was 8.54% in 2025; the steepest drop was 61.1% in 2025.
  • Year by year, Income from Continuing Operations stood at 13415000.0 in 2023, then dropped by 23.55% to 16574000.0 in 2024, then dropped by 8.54% to 17990000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for CMPX at 17990000.0 in Q4 2025, 15817000.0 in Q3 2025, and 21066000.0 in Q2 2025.